Latus is delighted to announce its partnership with
Cancer Research UK, LifeArc & University of Edinburgh
Latus has refocused its core activity from oncology R&D to identify, promote and facilitate the evaluation of treatments for COVID-19. This not for profit project orchestrated by Latus will assess the effectiveness of the existing drugs, Camostat and Nafamostat, to fight the virus.
Latus established a collaboration with Ono Pharmaceutical and Nichi-Iko Pharmaceutical for drugs provision and secured £1m from LifeArc to support clinical evaluation. Latus will now be supported by Cancer Research UK and the University of Edinburgh to implement the SPIKE-1 and SPIKE-2 trials, respectively.
SPIKE trials are designed to be
Because Camostat is an established drug
This means it is already cleared as safe to use, dramatically reducing lead times
Because Camostat is taken as a tablet: two tablets four times a day for two weeks
We have the production capacity to make camostat available for 63 million patients immediately
That is sufficient to cover the entire population of the UK
Early discussions with manufacturers suggest that production could be significantly scaled up in the short-medium term, as needed
Because we are trialling a drug to alleviate the symptoms of Covid-19
If successful, we have the potential to be able to manage Covid-19 symptoms just like common flu